|
1
|
Reikvam H, Steien E, Hauge B, Liseth K,
Hagen KG, Størkson R and Hervig T: Thrombelastography. Transfus
Apheresis Sci. 40:119–123. 2009. View Article : Google Scholar
|
|
2
|
Craft RM, Chavez JJ, Bresee SJ, Wortham
DC, Cohen E and Carroll RC: A novel modification of the
thrombelastograph assay, isolating platelet function, correlates
with optical platelet aggregation. J Lab Clin Med. 143:301–309.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Patti G, Grieco D, Dicuonzo G, Pasceri V,
Nusca A and Di Sciascio G: High versus standard clopidogrel
maintenance dose after percutaneous coronary intervention and
effects on platelet inhibition, endothelial function, and
inflammation results of the ARMYDA-150 mg (antiplatelet therapy for
reduction of myocardial damage during angioplasty) randomized
study. J Am Coll Cardiol. 57:771–778. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Stewart RAH, Colquhoun DM, Marschner SL,
Kirby AC, Simes J, Nestel PJ, Glozier N, O'Neil A, Oldenburg B,
White HD, et al LIPID Study Investigators, : Persistent
psychological distress and mortality in patients with stable
coronary artery disease. Heart. 103:1860–1866. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Chen KJ and Liu Y: Stable coronary heart
disease: A choice for PCI or drug therapy - inspiration from
results of a new meta-analysis. Zhongguo Zhong Xi Yi Jie He Za Zhi.
32:583–584. 2012.(In Chinese). PubMed/NCBI
|
|
6
|
Khan AR, Golwala H, Tripathi A, Riaz H,
Kumar A, Flaherty MP and Bhatt DL: Meta-analysis of percutaneous
coronary intervention versus coronary artery bypass grafting in
left main coronary artery disease. Am J Cardiol. 119:1949–1956.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ford NF and Taubert D: Clopidogrel,
CYP2C19, and a black box. J Clin Pharmacol. 53:241–248. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Duzenli MA, Ozdemir K, Aygul N, Soylu A
and Tokac M: Comparison of increased aspirin dose versus combined
aspirin plus clopidogrel therapy in patients with diabetes mellitus
and coronary heart disease and impaired antiplatelet response to
low-dose aspirin. Am J Cardiol. 102:396–400. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zhang L, Yang J, Zhu X, Wang X, Peng L, Li
X, Cheng P and Yin T: Effect of high-dose clopidogrel according to
CYP2C19*2 genotype in patients undergoing percutaneous coronary
intervention- a systematic review and meta-analysis. Thromb Res.
135:449–458. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Chen S, Zhang Y, Wang L, Geng Y, Gu J, Hao
Q, Wang H and Qi P: Effects of dual-dose clopidogrel, clopidogrel
combined with tongxinluo capsule, and ticagrelor on patients with
coronary heart disease and CYP2C19*2 gene mutation after
percutaneous coronary interventions (PCI). Med Sci Monit.
23:3824–3830. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Xu L, Wang L, Yang X, Li K, Sun H, Zhang
D, Wang H, Li W, Ni Z, Xia K, et al: Platelet function monitoring
guided antiplatelet therapy in patients receiving high-risk
coronary interventions. Chin Med J (Engl). 127:3364–3370.
2014.PubMed/NCBI
|
|
12
|
Louis SG, Van PY, Riha GM, Barton JS,
Kunio NR, Underwood SJ, Differding JA, Rick E, Ginzburg E and
Schreiber MA: Thromboelastogram-guided enoxaparin dosing does not
confer protection from deep venous thrombosis: A randomized
controlled pilot trial. J Trauma Acute Care Surg. 76:937–942;
discussion 942–943. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Jolliffe JA, Rees K, Taylor RS, Thompson
D, Oldridge N and Ebrahim S: Exercise-based rehabilitation for
coronary heart disease. Cochrane Database Syst Rev.
1:CD0018002001.
|
|
14
|
Anderson JL, Adams CD, Antman EM, Bridges
CR, Califf RM, Casey DE Jr, Chavey WE II, Fesmire FM, Hochman JS,
Levin TN, et al 2011 Writing Group Members; ACCF/AHA Task Force
Members, : 2011 ACCF/AHA focused update incorporated into the
ACC/AHA 2007 guidelines for the management of patients with
unstable angina/non-ST-elevation myocardial infarction: A report of
the American College of Cardiology Foundation/American Heart
Association Task Force on Practice Guidelines. Circulation.
123:e426–e579. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kishan PV, Uday KC, Shobha JC, Usharani P
and Chandrasekhar E: Effect of oral anti-platelet regimens on
platelet aggregation using chronolog light transmittance
aggregometry in coronary heart disease patients: An observational
study. J Clin Diagn Res. 7:2478–2482. 2013.PubMed/NCBI
|
|
16
|
Steg PG, James S, Harrington RA, Ardissino
D, Becker RC, Cannon CP, Emanuelsson H, Finkelstein A, Husted S,
Katus H, et al PLATO Study Group, : Ticagrelor versus clopidogrel
in patients with ST-elevation acute coronary syndromes intended for
reperfusion with primary percutaneous coronary intervention: A
Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup
analysis. Circulation. 122:2131–2141. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Hiller KN: Clinically relevant exaggerated
pharmacodynamic response to dual antiplatelet therapy detected by
Thromboelastogram® Platelet Mapping™. J Anaesthesiol
Clin Pharmacol. 32:112–114. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Jain R and Sood J: Antiplatelet therapy in
patients with coronary artery stents for noncardiac surgery: Role
of thromboelastography. J Anaesthesiol Clin Pharmacol. 27:537–540.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zhao SW, Wang YP, Xu LD and Gang W: The
application of thromboelastogram in detection of indexes of
antiplatelet therapy for coronary heart disease. J Thorac Dis.
8:3515–3520. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Yildirim F, Tuncer B, Ozbakkaloglu A,
Kurdal AT, Ozturk T and Iskesen I: Thromboelastogram reduces blood
use by inspecting coagulation in heart surgery. Asian Cardiovasc
Thorac Ann. 24:441–444. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Berezovskaya G, Smirnova O, Malev E,
Khromov-Borisov N, Klokova E, Karpenko M, Papayan L and Petrishchev
N: Thrombin generation test for evaluation of antiplatelet
treatment in patients with coronary artery disease after
percutaneous coronary intervention. Platelets. 29:185–191. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Gurbel PA, Bliden KP, Kreutz RP, Dichiara
J, Antonino MJ and Tantry US: The link between heightened
thrombogenicity and inflammation: Pre-procedure characterization of
the patient at high risk for recurrent events after stenting.
Platelets. 20:97–104. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Gurbel PA, Bliden KP, Navickas IA, Mahla
E, Dichiara J, Suarez TA, Antonino MJ, Tantry US and Cohen E:
Adenosine diphosphate-induced platelet-fibrin clot strength: A new
thrombelastographic indicator of long-term poststenting ischemic
events. Am Heart J. 160:346–354. 2010. View Article : Google Scholar : PubMed/NCBI
|
